President-elect Trump is considering Scott Gottlieb, a health investor at New Enterprise Associates, to run the U.S. Food and Drug Administration, Reuters reports.
Gottlieb, unlike another contender, Jim O’Neill, has a medical research background: He was a former deputy commissioner at FDA. Gottlieb is also a frequent commentator on health policy and a regular contributor to Forbes, where he has criticized aspects of the Affordable Care Act.